Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Oligodendroglioma 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Specimen Handling 625pembrolizumab 606Magnetic Resonance Spectroscopy 550Carboplatin 448Cisplatin 396Cyclophosphamide 394Biopsy 371Paclitaxel 323Nivolumab 322Gemcitabine 317Radiotherapy 283Bevacizumab 242Dexamethasone 222fludarabine 213Docetaxel 198durvalumab 194Oxaliplatin 187venetoclax 186atezolizumab 179Fluorouracil 176Rituximab 175Pemetrexed 172Capecitabine 167Radiation 164Doxorubicin 164Radiosurgery 159Ipilimumab 145Etoposide 142Leucovorin 140Lenalidomide 138

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × vocimagene amiretrorepvec × 90 days × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

NCT06504381 2026-03-11

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

University of California, San Francisco

Phase 1/2 Recruiting
70 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡